Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

National and regional population-based registries are, provided diagnostic accuracy and full
coverage of the target population, indispensible tools for epidemiological research. Chronic …

In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year
overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to …

Patients with estrogen receptor (ER)-positive breast cancer are at risk of metastatic relapse
for decades after primary tumor resection and treatment, a consequence of dormant …

This population-based registry was designed to provide robust and updated information on
the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of …

Several guidelines and recommendations on the management of chronic myeloid leukemia
(CML) have been prepared by several scientific societies. The European LeukemiaNet …

Patients with chronic myeloid leukemia develop resistance to both first-generation and
second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase …

Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a
BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid …

BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine
kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a …